| Identification | Back Directory | [Name]
Butanediamide,N1-hydroxy-2-methyl-N4-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-3-(2-methylpropyl)-,(2S,3R)- | [CAS]
168158-16-5 | [Synonyms]
Butanediamide,N1-hydroxy-2-methyl-N4-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-3-(2-methylpropyl)-,(2S,3R)- | [Molecular Formula]
C18H27N3O4 | [MOL File]
168158-16-5.mol | [Molecular Weight]
349.42 |
| Hazard Information | Back Directory | [Description]
KB-R7785 is a novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the inhibition of TNF-alpha production. |
|
|